Epidemiology of drug resistant epilepsy in adults
https://doi.org/10.20538/1682-0363-2018-3-207-216
Abstract
This review examines the epidemiology of drug resistant epilepsy in adults in Russia and abroad. References were taken from Russian and foreign databases for the period from 2010–2017. Only full-text publications (66) were included in this review. We concluded that the despite the achievements of clinical pharmacology and the development of new antiepileptic drugs, the problem of drug resistant epilepsy remains not fully resolved today. The worldwide high prevalence rate of patients with drug resistant epilepsy substantiates the problem. Thus, the average incidence of this disease varies from 30% to 70%, depending on the type of epilepsy and background pathology, which is the cause of symptomatic epilepsy. However, we have faced the problem of the absence both in Russia and abroad of large multicenter studies on the epidemiology of drug resistant epilepsy in the analyzed period of time. We have also revealed the lack of a unified definition of the disease, which is probably one of the reasons for the insufficient number of epidemiological studies of drug resistant epilepsy in different countries of the world.
About the Authors
E. A. Narodova
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical Universit (KSMU)
Russian Federation
Russian Federation
Narodova Ekaterina A. - PhD, Division of Nervous Diseases and Medical Rehabilitation.
1, Partizan Zheleznyak Str., Krasnoyarsk, 660022
N. A. Shnayder
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical Universit (KSMU)
Russian Federation
Russian Federation
Shnayder Natalia A. - DM, Professor, Head of the Division of Medical Genetics and Clinical Neurophysiology.
1, Partizan Zheleznyak Str., Krasnoyarsk, 660022
S. V. Prokopenko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical Universit (KSMU)
Russian Federation
Russian Federation
Prokopenko Semyon V. - DM, Professor, Head of the Division of Nervous Diseases and Medical Rehabilitation.
1, Partizan Zheleznyak Str., Krasnoyarsk, 660022
V. V. Narodova
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical Universit (KSMU)
Russian Federation
Russian Federation
Narodova Valeriya V. - DM, Professor, Division of Nervous diseases and Medical Rehabilitation.
1, Partizan Zheleznyak Str., Krasnoyarsk, 660022
A. A. Narodov
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical Universit (KSMU)
Russian Federation
Russian Federation
Narodov Andrey A. - DM, Professor, Division of Traumatology, Orthopedic, and Neurosurgery.
1, Partizan Zheleznyak Str., Krasnoyarsk, 660022
D. V. Dmitrenko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical Universit (KSMU)
Russian Federation
Russian Federation
Dmitrenko Diana V. - DM, Associate Professor, Division of Medical Genetics and Clinical Neurophysiology.
1, Partizan Zheleznyak Str., Krasnoyarsk, 660022
References
1. Banerjee P.N., Filippi D., Allen Hauser W. The descriptive epidemiology of epilepsy – a review. Epilepsy Res. 2009; 85 (1): 31–45. DOI: 10.1016/j.eplepsyres.2009.03.003.
2. Picot M.C., Baldy-Moulinier M., Daurès J.P., Dujols P., Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia. 2008; 49 (7): 1230– 1238. DOI:10.1111/j.1528-1167.2008.01579.x.
3. Laxer K.D., Trinka E., Hirsch L.J., Cendes F., Langfitt J., Delanty N., Resnick T., Benbadis S.R. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014; 37: 59–70. DOI:10.1016/j.yebeh.2014.05.031.
4. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., Moshé S.L., Perucca E., Wiebe S., French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51 (6): 1069–1077 [Erratum in: Epilepsia 2010; 51: 1922]. DOI: 10.1111/j.1528-1167.2009.02397.x.
5. Berg A.T., Levy S.R., Testa F.M., D’Souza R. Remission of epilepsy after two drug failures in children: a prospective study. Ann. Neurol. 2009; 65 (5): 510–519. DOI:10.1002/ana.21642.
6. Sillanpää M., Schmidt D. Is incident drug-resistance of childhood-onset epilepsy reversible? A long-term follow-up study. Brain. 2012; 135 (Pt. 7): 2256–2262. DOI:10.1093/brain/aws062.
7. Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission. Arch. Neurol. 2009; 66 (10): 1233–1239. DOI: 10.1001/archneurol.2009.211.
8. Wiebe S., Blume W.T., Girvin J.P., Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med. 2001; 345 (5): 311–318. DOI: 10.1056/NEJM200108023450501.
9. Engel J.Jr., McDermott M.P., Wiebe S., Langfitt J.T., Stern J.M., Dewar S., Sperling M.R., Gardiner I., Erba G., Fried I., Jacobs M., Vinters H.V., Mintzer S., Kieburtz K. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012; 307 (9): 922– 930. DOI: 10.1001/jama.2012.220.
10. Dobesberger J., Walser G., Unterberger I., Seppi K., Kuchukhidze G., Larch J., Bauer G., Bodner T., Falkenstetter T., Ortler M., Luef G., Trinka E. Video-EEG monitoring: safety and adverse events in 507 consecutive patients. Epilepsia. 2011; 52 (3): 443–452. DOI: 10.1111/j.1528-1167.2010.02782.x.
11. Hedegärd E., Bjellvi J., Edelvik A., Rydenhag B., Flink R., Malmgren K. Complications to invasive epilepsy surgery workup with subdural and depth electrodes: a prospective population-based observational study. J. Neurol. Neurosurg. Psychiatry. 2014; 85 (7): 716–720. DOI: 10.1136/jnnp-2013-306465.
12. Ehling R., Dobesberger J., Unterberger I., Benke T., Gotwald T., Ortler M., Berger T., Trinka E. Selective amydalo-hippocampectomy as a potential trigger for disease progression in multiple sclerosis. Clin. Neurol. Neurosurg. 2011; 113 (2): 136–138. DOI: 10.1016/j.clineuro.2010.08.004.
13. Endo Y., Saito Y., Otsuki T., Takahashi A., Nakata Y., Okada K., Hirozane M., Kaido T., Kaneko Y., Takada E., Okazaki T., Enokizno T., Saito T., Komaki H., Nakagawa E., Sugai K., Sasaki M. Persistent verbal and behavioral deficits after resection of the left supplementary motor area in epilepsy surgery. Brain Dev. 2014; 36 (1): 74–79. DOI: 10.1016/j.braindev.2013.01.002.
14. Georgiadis I., Kapsalaki E.Z., Fountas K.N. Temporal lobe resective surgery for medically intractable epilepsy: a review of complications and side effects. Epilepsy Res. Treat. 2013: 752195. DOI: 10.1155/2013/752195 [E-pub ahead of print 2013 Oct. 31].
15. Roth J., Carlson C., Devinsky O., Harter D.H., Macallister W.S., Weiner H.L. Safety of Staged Epilepsy Surgery in Children. Neurosurgery. 2014; 74 (2): 154–162. DOI: 10.1227/NEU.0000000000000231.
16. Hao X., Goldberg D., Kelly K., Stephen L., Kwan P., Brodie M.J. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy Behav. 2013; 29 (1): 4–6. DOI: 10.1016/j.yebeh.2013.06.019.
17. Chadwick D., Smith D. The misdiagnosis of epilepsy. BMJ. 2002; 324 (7336): 495–496.
18. Kanner A.M. Common errors made in the diagnosis and treatment of epilepsy. Semin. Neurol. 2008; 28 (3): 364– 378. DOI: 10.1055/s-2008-1079341.
19. Leach J.P., Lauder R., Nicolson A., Smith D.F. Epilepsy in the UK: misdiagnosis, mistreatment, and undertreatment? The Wrexham area epilepsy project. Seizure. 2005; 14 (7): 514–520. DOI: 10.1016/j.seizure.2005.08.008.
20. Kwan P., Schachter S.C., Brodie M.J. Drug-resistant epilepsy. N. Engl. J. Med. 2011; 365 (10): 919–926. DOI: 10.1056/NEJMra1004418.
21. Mamatkhanov M.R., Lebedev K.E., Sebelev K.I. Neuroimaging in the surgical treatment of drug-resistant epilepsy in children. Pediatric Neurosurgery and Neurology. 2011; (3): 10–17 (in Russ.).
22. Karlov V.A. Epilepsy in children and adults, women and men: a guide for doctors. M.: Medicina Publ., 2010: 720 (in Russ.).
23. Rudakova I.G., Belova Ju.A., Kotov A.S. Drug resistant epilepsy is treatable. Vestnik jepileptologii. 2013; (1): 3–7 (in Russ.).
24. Shi L.L., Dong J., Ni H., Geng J., Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database of Syst. Rev. 2014; (7): CD008295. DOI: 10.1002/14651858.CD008295.pub3.
25. Pati S., Alexopoulos A.V. Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies. Cleve. Clin. J. Med. 2010; 77 (7): 457–467. DOI: 10.3949/ccjm.77a.09061.
26. Murgia F., Muroni A., Puligheddu M., Polizzi L., Barberini L., Orofino G., Solla P., Poddighe S., Del Carratore F., Griffin J.L., Atzori L., Marrosu F. Metabolomics аs a tool for the сharacterization of drug-resistant еpilepsy. Front. Neurol. 2017; (8): 459. DOI: 10.3389/fneur.2017.00459.
27. Abimbola S., Martiniuk A.L., Hackett M.L., Anderson C.S. The influence of design and definition on the proportion of general epilepsy cohorts with remission and intractability. Neuroepidemiology. 2011; 36 (3): 204–212. DOI: 10.1159/000327497.
28. Avakyan G.N. Issues of modern epileptology. Epilepsia and Paroxyzmal Conditions. 2015; 7 (4): 16–21. (in Russ.). DOI: 10.17749/2077-8333.2015.7.4.016-021.
29. Moshé S.L., Perucca E., Ryvlin P., Tomson T. Epilepsy: new advances. Lancet. 2015; 385 (9971): 884–898. DOI: 10.1016/S0140-6736(14)60456-6. 30. Shorvon S.D. Handbook of еpilepsy treatment. Singapore: 3rd ed. N.Y.: Wiley-Blackwell, 2010: 431. DOI: 10.1002/9781444325201.
30. Shnayder N.A., Pilyugina M.S., Dmitrenko D.V., Shmatova E.N., Erykalova S.A. The personalized approach to the epilepsy treatment reduces the incidence of drug resistance. Biomedicine. 2010; (3): 172–174 (in Russ.).
31. Nasyrova R.F., Sivakova N.A., Lipatova L.V., Ivashchenko D.V., Sosina K.A.,Drokov A.P., Shnayder N.A. Biological markers of the antiepileptic drugs efficacy and safety: pharmacogenetics and pharmacokinetics. Siberian Medical Review. 2017; (1): 17–25 (in Russ.). DOI: 10.20333/2500136-2017-1-17-25.
32. Schnayder N.A., Dmitrenko D.V., Govorina Y.B., Muraveva A.V., Kotlovsky J.V., Bochanova E.N., Fateeva E.A., Dedyuk N.A., Mustafayeva A.V. Effect of polymorphisms in the CYP2C9 gene on valproic acid levels in the blood of women’s in a reproductive age with epilepsy. Pharmacogenetics and Pharmacogenomics. 2015; (2): 24–28 (in Russ.).
33. Kryzhanovskij G.N. General pathophysiology of the nervous system: guidance. Moskow: Medicina Publ., 1997: 352 (in Russ.).
34. Goddard G.V. Development of epileptic seizures through brain stimulation at low intensity. Nature. 1967; 214 (5092): 1020–1021.
35. Sato M., Nakashima T. Kindling: secondary epileptogenesis, sleep and catecholamines. Can. J. Neurol. Sci. 1975; 2 (4): 439–446.
36. Mohanraj R., Brodie M.J. Early predictors of outcome in newly diagnosed epilepsy. Seizure. 2013; 22 (5): 333– 344. DOI: 10.1016/j.seizure.2013.02.002.
37. Trinka E., Bauer G., Oberaigner W., Ndayisaba J.P., Seppi K., Granbichler C.A. Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. Epilepsia. 2013; 54 (3): 495–501. DOI: 10.1111/epi.12014.
38. Berg A.T., Nickels K., Wirrell E.C., Geerts A.T., Callenbach P.M., Arts W.F., Rios C., Camfield P.R., Camfield C.S. Mortality risks in new-onset childhood epilepsy. Pediatrics. 2013; 132 (1): 124–131. DOI:10.1542/peds.2012-3998.
39. Ding D., Wang W., Wu J., Yang H., Li S., Dai X., Yang B., Wang T., Yuan C., Ma G., Bell G.S., Kwan P., de Boer H.M., Hong Z., Sander J.W. Premature mortality risk in people with convulsive epilepsy: long follow-up of a cohort in rural China. Epilepsia. 2013; 54 (3): 512–517. DOI:10.1111/epi.12048.
40. Fazel S., Wolf A., Lеngström N., Newton C.R., Lichtenstein P. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet. 2013; 382 (9905): 1646–1654. DOI: 10.1016/S01406736(13)60899-5.
41. Holst A.G., Winkel B.G., Risgaard B., Nielsen J.B., Rasmussen P.V., Haunsø S., Sabers A., Uldall P., Tfelt-Hansen J. Epilepsy and risk of death and sudden unexpected death in the young: a nationwide study. Epilepsia. 2013; 54 (9): 1613–1620. DOI: 10.1111/epi.12328.
42. Nevalainen O., Raitanen J., Ansakorpi H., Artama M., Isojärvi J., Auvinen A. Long-term mortality risk by cause of death in newly diagnosed patients with epilepsy in Finland: a nationwide register-based study. Eur. J. Epidemiol. 2013; 28 (12): 981–990. DOI: 10.1007/s10654-0139848-1.
43. Novy J., Belluzzo M., Caboclo L.O., Catarino C.B., Yogarajah M., Martinian L., Peacock J.L., Bell G.S., Koepp M.J., Thom M., Sander J.W., Sisodiya S.M. The lifelong course of chronic epilepsy: the Chalfont experience. Brain. 2013; 136 (Pt 10): 3187–3199. DOI: 10.1093/brain/awt117.
44. Shorvon S.D., Goodridge D.M. Longitudinal cohort studies of the prognosis of epilepsy: contribution of the National General Practice Study of Epilepsy and other studies. Brain. 2013; 136 (11): 3497–3510. DOI: 10.1093/brain/awt223.
45. Sillanpää M., Shinnar S. SUDEP and other causes ofmortality in childhood-onset epilepsy. Epilepsy Behav. 2013; 28 (2): 249–255. DOI: 10.1016/j.yebeh.2013.04.016.
46. So E. Summary of Session I: Mortality in Epilepsy [Electronic resource]. In: Partners Against Mortality in Epilepsy Conference Summary. Epilepsy Curr. 2013; 13 (2): 6–8. URL: https://www.aesnet.org/sites/default/files/file_attach/Epilepsy%20Currents%2013-s2-1%20PAME%20supplement.pdf
47. Sillanpää M., Shinnar S. Long-term mortality in childhood-onset epilepsy. N. Engl. J. Med. 2010; 363 (26): 2522–2529. DOI: 10.1056/NEJMoa0911610.
48. Bernhardt B.C.,Worsley K.J., Kim H., Evans A.C., Bernasconi A., Bernasconi N. Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy. Neurology. 2009; 72 (20): 1747–1754. DOI: 10.1212/01.wnl.0000345969.57574.f5.
49. Coan A.C., Appenzeller S., Bonilha L., Li L.M., Cendes F. Seizure frequency and lateralization affect progression of atrophy in temporal lobe epilepsy. Neurology. 2009; 73 (11): 834–842. DOI:10.1212/WNL.0b013e3181b783dd.
50. Shinnar S., Bello J.A., Chan S., Hesdorffer D.C., Lewis D.V., Macfall J., Pellock J.M., Nordli D.R., Frank L.M., Moshe S.L., Gomes W., Shinnar R.C., Sun S. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study. Neurology. 2012; 79 (9): 871–877. DOI: 10.1212/WNL.0b013e318266fcc5.
51. Yasuda C.L., Morita M.E., Alessio A., Pereira A.R., Balthazar M.L., Saúde A.V., Costa A.L., Costa A.L., Cardoso T.A., Betting L.E., Guerreiro C.A., Damasceno B.P., Lopes-Cendes I., Tedeschi H., de Oliveira E., Cendes F. Relationship between environmental factors and gray matter atrophy in refractory MTLE. Neurology. 2010; 74 (13): 1062–1068. DOI: 10.1212/WNL.0b013e3181d76b72.
52. Conz L., Morita M.E., Coan A.C., Kobayashi E., Yasuda C.L., Pereira A.R., Lopes-Cendes I., Cendes F. Longitudinal MRI volumetric evaluation in patients with familial mesial temporal lobe epilepsy. Front. Neurol. 2011; 2: 5. DOI: 10.3389/fneur.2011.00005.
53. Labate A., Cerasa A., Aguglia U., Mumoli L., Quattrone A., Gambardella A. Neocortical thinning in “benign” mesial temporal lobe epilepsy. Epilepsia. 2011; 52 (4): 712–717. DOI: 10.1111/j.1528-1167.2011.03038.x.
54. Campos B.A., Yasuda C.L., Castellano G., Bilevicius E., Li L.M., Cendes F. Proton MRS may predict AED response in patients with TLE. Epilepsia. 2010; 51 (5): 783–788. DOI: 10.1111/j.1528-1167.2009.02379.x.
55. Mueller S.G., Ebel A., Barakos J., Scanlon C., Cheong I., Finlay D., Garcia P., Weiner M.W., Laxer K.D. Widespread extrahippocampal NAA/(Cr+Cho) abnormalities in TLE with and without mesial temporal sclerosis. J. Neurol. 2011; 258 (4): 603–612. DOI: 10.1007/s00415010-5799-6.
56. Scanlon C., Mueller S.G., Cheong I., Hartig M., Weiner M.W., Laxer K.D. Grey and white matter abnormalities in temporal lobe epilepsy with and without mesial temporal sclerosis. J. Neurol. 2013; 260 (9): 2320–2329. DOI: 10.1007/s00415-013-6974-3.
57. Yasuda C.L., Valise C., Saúde A.V., Pereira A.R., Pereira F.R., Ferreira Costa A.L., Morita M.E., Betting L.E., Castellano G., Mantovani Guerreiro C.A., Tedeschi H., de Oliveira E., Cendes F. Dynamic changes in white and gray matter volume are associated with outcome of surgical treatment in temporal lobe epilepsy. Neuroimage. 2010; 49 (1): 71–79. DOI: 10.1016/j.neuroimage.2009.08.014.
58. Fahoum F., Lopes R., Pittau F., Dubeau F., Gotman J. Widespread epileptic networks in focal epilepsies-EEG-fMRI study. Epilepsia. 2012; 53 (9): 1618–1627. DOI: 10.1111/j.1528-1167.2012.03533.x.
59. Malmgren K., Thom M. Hippocampal sclerosis–origins and imaging. Epilepsia. 2012; 53 (Suppl. 4): 19–33. DOI: 10.1111/j.1528-1167.2012.03610.x.
60. Morita M.E., Yasuda C.L., Betting L.E., Pacagnella D., Conz L., Barbosa P.H., Maurer-Morelli C.V., Costa A.L., Kobayashi E., Lopes-Cendes I., Cendes F. MRI and EEG as long-term seizure outcome predictors in familial mesial temporal lobe epilepsy. Neurology. 2012; 79 (24): 2349–2354. DOI: 10.1212/WNL.0b013e318278b63f.
61. Bilevicius E., Yasuda C.L., Silva M.S., Guerreiro C.A., Lopes-Cendes I., Cendes F. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology. 2010; 75 (19): 1695–1701. DOI: 10.1212/WNL.0b013e3181fc29dd.
62. Shnayder N.A. Some aspects of sudden death syndrome in epilepsy. Sovremennye medicinskie tehnologii. 2010; (5): 55–59 (in Russ.).
63. Shchederkina I.O., Orlova K.A., Koltunov I.E., Dorofeeva M. Yu. Efficacy of rufinamide in the treatment of drug-resistant focalepilepsies in paediatric practice. Russian Journal of Child Neurology. 2016; 11 (4): 54–60 (in Russ.). DOI: 10.17650/2073-8803-2016-11-4-54-60.
64. Lekomtsev V.T. Defects of treatment of farmakorezistentny epilepsies within medical examinations. Medical Examination Problems. 2015; 15 (3–4): 34–36 (in Russ.).
65. Bochanova E.N. Pharmacogenetics of antiepileptic drugs (literature review). Kachestvennaja klinicheskaja praktika. 2017; (1): 51–55 (in Russ.).
66. Banerjee J., Tripathi M., Chandra P.S. Understanding complexities of synaptic transmission in medically intractable seizures: A paradigm of epilepsy research. Indian. J. Neurosurg. 2013; (2): 71–76.
67. Asadi-Pooya A.A., Stewart G.R., Abrams D.J., Sharan A. Prevalence and incidence of drug-resistant mesial temporal lobe еpilepsy in the United States. World Neurosurg. 2017; 99: 662–666. DOI: 10.1016/j.wneu.2016.12.074.
68. Martínez-Juárez I.E., Lуpez-Zapata R., Gуmez-Arias B., Bravo-Armenta E., Romero-Ocampo L., Estévez-Cruz Z., Hernández-De la Cruz G., Morán-Molina S. Refractory epilepsy: use of the new definition and related risk factors. A study in the Mexican population of a third-level centre. Rev. Neurol. 2012; 54 (3): 159–166.
69. Nadkarni S., Lajoile J., Devinsky O. Current Treatments of epilepsy. Neurology. 2005; 64 (12 Suppl 3): S2–S11.
70. Orozco-Hernández J.P., Quintero-Moreno J.F., Marín-Medina D.S., Castaсo-Montoya J.P., Hernández-Coral P., Pineda M., Vélez J.D., Villada H.C., Martínez J.W., Lizcano A. Clinical and sociodemographic profile of epilepsy in adults from a reference centre in Colombia. Neurologia. 2017; pii: S0213–4853 (17) 30151-2. DOI: 10.1016/j.nrl.2017.02.013. [Epub ahead of print].
71. Giussani G., Canelli V., Bianchi E., Franchi C., Nobili A., Erba G., Beghi E. A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy Behav. 2016; 55: 30–37. DOI:10.1016/j.yebeh.2015.11.021.
72. Epilepsia de difícil control; eds. J.C. Sánchez-Álvarez, V. Villanueva Haba. Barcelona: Viguera Editores SL, 2010: 1–34.
73. Vespignani H., de Zélicourt M., Laurendeau C., Fagnani F., Levy-Bachelot L., Murat C., Kahane P., de Toffol B. Adult patients treated for focal epilepsy with antiepileptic drugs (AEDs) in combination in France: description according to the 2009 ILAE definition of AED resistance (ESPERA study)]. Rev. Neurol. (Paris). 2014; 170 (2): 100–109. DOI: 10.1016/j.neurol.2013.10.009.
74. Farghaly W.M., El-Tallaw H.N., Rageh T.A., Mohamed E.M., Metwally N.A., Shehata G.A., Badry R., Abd-Elhamed M.A. Epidemiology of uncontrolled epilepsy in the Al-Kharga District, New Valley, Egypt. Seizure. 2013; 22 (8): 611–616. DOI:10.1016/j.seizure.2013.04.010.
75. Tripathi M., Padhy U.P., Vibha D., Bhatia R., Padma Srivastava M.V., Singh M.B., Prasad K., Sarat P., Chandra S.P. Predictors of refractory epilepsy in North India: A case-control study. Seizure. 2011; 20 (10): 779–783. DOI: 10.1016/j.seizure.2011.07.010.
76. Kong S.T., Ho C.S., Ho P.C., Lim S.H. Prevalence of drug resistant epilepsy in adults with epilepsy attending a neurology clinic of a tertiary referral hospital in Singapore. Epilepsy Res. 2014; 108 (7): 1253–1262. DOI: 10.1016/j.eplepsyres.2014.05.005.
77. Guekht A.B., Milchakova L.E., Churilin Yu.Yu., Boiko A.N., Golovanova I.V., Shprakh V.V., Kabakov R.M., Balkhanova R., Kotov S.V., Kotov A.S., Spirin N.N., Pizova N.V., Volkova L.I., Perunova N.N., Gusev E.I. The epidemiology of epilepsy in Russia. S.S. Korsakov Journal of Neurology and Psychiatry. 2006; (Suppl. 1: Epilepsia): 37 (in Russ.).
78. Shnayder N.A., Pilugina M.S., Dmitrenko D.V., Shmatova E.N., Erikalova S.A. Incidence of pharmacoresistant epilepsy in Krasnoyarsk region (according to neurological center of university hospital data). Epilepsia and Paroxyzmal Conditions. 2010; 2 (4): 32i36 (in Russ.).
Review
For citations:
Narodova E.A., Shnayder N.A., Prokopenko S.V., Narodova V.V., Narodov A.A., Dmitrenko D.V. Epidemiology of drug resistant epilepsy in adults. Bulletin of Siberian Medicine. 2018;17(3):207-216. (In Russ.) https://doi.org/10.20538/1682-0363-2018-3-207-216
Views:
1134
Email this article 